Sydney, April 2025 – Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released a new report analyzing the evolving infectious disease clinical trial landscape. This report provides critical strategic insights for pharmaceutical and biotech companies navigating the complexities of global infectious disease research and development in 2025. 

Navigating the Future of Infectious Disease Clinical Trials 

Between 2020 and 2024, the infectious disease clinical trial sector experienced significant global growth, with nearly 2,000 industry-sponsored trials initiated, ongoing, or planned. The Asia-Pacific region is leading this expansion with a 70% compound annual growth rate (CAGR), driven by strong government support and global partnerships. North America follows with a 52% CAGR, fueled by substantial biotech investment. Europe and the rest of the world continue to show steady progress, contributing to a geographically diverse and increasingly robust global clinical trial landscape. 

Key findings: 

  • Global Clinical Trial Growth: Asia-Pacific dominates with 43% of global infectious disease trials, followed by North America (21%), Europe (20%), and ROW (16%). 
  • Therapeutic Focus Areas: Over 900 trials focused on viral infections such as COVID-19, HIV/AIDS, hepatitis B, and RSV, while bacterial and protozoal infections remain key research priorities. 
  • Technological Innovations: AI-driven drug discovery has accelerated development timelines by 60-70%, with decentralized clinical trials (DCTs) improving patient recruitment and retention. 
  • Antimicrobial Resistance (AMR) Challenge: AMR remains a critical public health threat, with limited industry investment slowing the development of novel antibiotics. 
  • Regulatory Harmonization & Platform Trials: Efforts such as WHO Prequalification programs and reliance pathways are expediting drug approvals, while platform trials are enhancing trial efficiency and cost-effectiveness. 

Addressing Industry Challenges & Opportunities 

While innovation in mRNA technology, gene-based therapies, and AI-driven drug discovery are advancing the treatment landscape for infectious disease, funding gaps continue to hinder antimicrobial research and neglected tropical disease (NTD) trials. Addressing these disparities through regulatory frameworks and strategic investment are essential to unlocking future innovation and ensuring sustainable growth across the global clinical trial ecosystem. 

Novotech: A Trusted Partner in Infectious Disease Clinical Development 

With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech supports biotech and pharmaceutical companies in accelerating infectious disease clinical development. 

Download the Full Report 

媒體聯絡人

關於Novotech Novotech-CRO.com

Novotech是一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司,自1997年成立以來,始終致力於為生物科技公司以及中小型製藥公司提供加速藥物上市的解決方案。公司在全球各地擁有30多個辦公據點,主要分佈在亞太地區、北美和歐洲,並與5000多個試驗機構建立了緊密的合作關係,為客戶提供豐富的臨床試驗資源網絡,幫助客戶輕鬆進軍關鍵試驗區域,廣泛接觸不同的受試者群體。Novotech運用其在臨床試驗領域與監管領域的專業能力,採取以客戶為中心的服務模式,充分利用本土市場洞察及先進分析工具,大幅加速了受試者招募,提高試驗效率,推動變革性療法來更快嘉惠患者。憑藉出色的表現,Novotech已榮獲多項殊榮,包括連續19年蟬聯Frost & Sullivan CRO年度公司獎。

如需瞭解更多資訊或與專家團隊成員交談,請造訪 www.Novotech-CRO.com